CHYM experienced a massive deterioration in profitability with net losses exploding from $22M to $55M quarterly and $6M to $965M on a nine-month basis, despite strong 52% revenue growth.
The dramatic swing from near-breakeven to nearly $1 billion in nine-month losses, combined with a 49% cash burn dropping reserves to $445M, raises serious questions about the company's path to profitability and cash runway. While revenue growth of 52% is impressive, the inability to control losses at this scale suggests fundamental operational or strategic challenges that could threaten the business model.
Despite strong top-line performance with revenue growing 52% to $1.6B and gross profit expanding proportionally, CHYM's financials deteriorated dramatically with nine-month net losses ballooning from $6M to $965M while R&D expenses increased 18% to $824M. The company's cash position collapsed 49% to $445M even as operating cash flow improved to $20M, and share count increased by 3.6M shares, indicating significant cash burn and potential dilution. This combination of massive loss expansion despite revenue growth, declining cash reserves, and increased spending suggests serious profitability challenges that could jeopardize the company's financial stability.
Operating cash flow surged 637.4% — exceptional cash generation, highest quality earnings signal.
Capital expenditure jumped 56.7% — major investment cycle underway; assess returns on deployment.
Strong top-line growth of 51.9% — accelerating demand or successful expansion into new markets.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Cash declined 48.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
R&D investment increased 17.7% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →